Novartis and Teva Pharmaceuticals, two of the defendants named in a wide-reaching lawsuit against generic drugmakers, have vowed to fight the allegations of price-fixing brought against them, according to a BioSpace news report.
In the lawsuit filed last week, 44 states attorneys general claim more than a dozen drugmakers conspired to inflate prices for more than 100 generic drugs by as much as 1,000 percent.
Novartis, which owns the Sandoz generic unit, disputed the claims and said it will fight the allegations, which it calls "baseless."
"We believe that these claims are without merit and will vigorously contest them,” Novartis told Reuters. "Sandoz takes its obligations under the antitrust laws seriously. We will continue to be committed to providing high quality, affordable medicines to U.S. patients, and conducting business with customers and the government with integrity."
Teva also denied the lawsuit allegations.
"Teva has not engaged in any conduct that would lead to civil or criminal liability," the company told The New York Times.